Article by DAN VERGANO of USA Today, originally published April 29, 2013.
Triggers growth of pancreatic ‘beta’ cells
A newly discovered mouse hormone may open the door to better treatment for diabetes, researchers suggested Thursday.
The hormone, called betatrophin, triggers the growth of pancreatic “beta” cells lost or ineffective in diabetes. Insulin is produced by beta cells in the pancreas.
Diabetes afflicts more than 25 million people nationwide, according to the American Diabetes Association. It is a condition that causes high blood sugar that can lead to heart disease, kidney failure and blindness.
In the journal Cell, a team led by Harvard’s Peng Yi reports that betatrophin can produce a roughly seventeenfold increase in these cells, and its increase may partly explain the rapid growth of these cells seen during pregnancy to feed developing fetuses in mammals, including people.
Other Readers Liked: Best Father’s Day Gift is Peace of Mind
“This is really an amazing discovery. Hormones with this kind of effect aren’t discovered very often, and this opens a whole new pathway to treating diabetes,” said diabetes expert Jake Kushner of the McNair Medical Institute at Baylor College of Medicine in Houston, who was not part of the study team.
The hormone was discovered almost by accident, as the Harvard team investigated a research compound that basically recreates what happens in diabetes. The compound short circuits the release of insulin in response to increasing blood sugar. When that happened to the mice in the study, their production of the hormone betatrophin ramped up and spurred the growth of insulin producing cells. Diabetics often need daily insulin injections to compensate for the condition, where in Type 2, or adult-onset diabetes, the most frequent kind, beta cells stop producing enough insulin, and in juvenile diabetes, or Type 1, about 10 percent of cases, beta cells have died.
“Of course, we are a long way from a treatment. But if this could be used in people, what I think it could mean eventually is that instead of taking insulin injections three times a day, you might take an injection of this hormone once a week or once a month,” said study senior author Doug Melton of the Harvard Stem Cell Institute, in a commentary provided by the university.
The study researchers acknowledge they don’t know exactly how the hormone spurs the growth of beta cells, whether directly or by triggering a cascade of activity that leads to more of them. The researchers have entered into agreement with two pharmaceutical firms, Evatec and Jansen, to investigate treatments with the hormone. The study was largely funded by research money from the 2009 federal stimulus, Melton said.